Wenbin Jiang, Ph.D. has served as Cytek’s Chief Executive Officer and a member of the Board since December 2014. Dr. Jiang is also a co-founder of the company. In 1998, Dr. Jiang co-founded E2O Communications, Inc., a fiber optic subsystems manufacturing company, which was acquired by JDS Uniphase Corporation in 2004.

Dr. Jiang is an inventor of 100 U.S. patents and an author of five book chapters and over 50 peer-reviewed technical papers.

Dr. Jiang is currently serving on the Board of Trustees of the UC Santa Barbara Foundation and the Director’s Council in the Institute for Energy Efficiency at UC Santa Barbara.

Dr. Jiang holds a B.S. in Physics and M.S. in Optics & Laser Physics from Fudan University and a Ph.D. in Electrical Engineering from University of California, Santa Barbara.

Jack Ball has served on our board of directors since September 2018 and as lead independent director until 2025. Mr. Ball also serves as the President of Tyball Associates LLC and serves on the board of directors of Carterra, Inc., a biotechnology company, KromaTiD, Inc., a biotechnology company. He also currently serves on the advisory board of Michigan Angel Fund V. From May 2021 to June 2023, Mr. Ball served on the board of directors of NanoCellect Biomedical, Inc., a biotechnology company.

From October 2010 to March 2021, Mr. Ball served on the board of directors of Swift Biosciences Inc., a biotechnology company. From September 2013 to December 2019, Mr. Ball served as Chief Executive Officer and a board member at Solulink Inc., a biotechnology company. From February 2006 to July 2011, Mr. Ball was Chief Commercial Officer at Accuri Cytometers, Inc., a medical instruments company, which was sold to Becton Dickinson in March 2011. Prior to that, Mr. Ball was Chief Executive Officer at Amnis Corporation, a biotechnology company, Chief Commercial Officer at Molecular Probes, Inc., a biotechnology company, Senior Vice President and General Manager at Orchid Biosciences, a DNA testing services biotechnology company, and President for North America at Amersham Pharmacia Biosciences Corp., a healthcare company.

Mr. Ball holds a B.S. in Agriculture from the University of Georgia.

Richard Chin, M.D., has served on our board of directors since 2025. Since 2021, he has served as the managing director of Ascendant Venture LLC, a family office and venture studio that has incubated several life sciences companies; since 2026, he has also served as the Chief Executive Officer of EmberWorks, LLC, an off-grid telecommunications company. He has also served as the Chief Executive Officer and a board member of AdoraPet Biosciences, Inc., a biotechnology startup focused on pets, since 2022. From 2012 to 2021, he served as Chief Executive Officer and a board member of Kindred Biosciences, Inc., a public biotechnology company focused on companion animals that was acquired by Elanco in 2021. From 2008 to 2011, Dr. Chin served as Chief Executive Officer of Institute for OneWorld Health, a nonprofit biotechnology company developing drugs for neglected diseases. In addition, from 2006 to 2008, he served as Chief Executive Officer of OXiGENE, Inc., a public biotechnology company developing vascular targeting drugs for oncology and ophthalmology. Prior to that, Dr. Chin served in various leadership roles in clinical development and medical affairs. He currently serves on the board of directors of several private biosciences companies, including Bio Usawa Inc., VETmAb Biosciences, Inc. and Lifeguard Biosciences, Inc., as well as two nonprofit organizations, the Center for Asian American Media and the Sand Mandala Foundation.

Dr. Chin holds a B.A. in biology from Harvard College, an M.A. and B.A. in law from Oxford University, and a medical degree from Harvard Medical School.

Michael Holder has served on our board of directors since June 2024. Since 2023, Mr. Holder has served as the Principal of Gloria Consulting Partners LLC, an executive management, business strategy, and financial consulting company. He also served as Chief Executive Officer of Sensable Health Inc., a privately held wellness company, from 2024 to 2025. Since May 2025, Mr. Holder serves as a member of the board of directors of MDxHealth SA, a publicly traded molecular oncology company, and, since July 2025, as non-executive chair and member of the board of directors of Hollywood Expansion Corporation, a privately held film and entertainment company. Mr. Holder also served as a member of the board of directors of Keyron Ltd, a privately held medical device company based in the U.K., from 2022 to 2025. Prior to that, Mr. Holder served as Chief Financial Officer of AVITA Medical Inc., a publicly traded regenerative medicine company, from 2021 to 2023; as Chief Financial Officer of ImmuneCyte Inc., a privately held biopharmaceutical company, from 2020 to 2021; as Chief Executive Officer and Portfolio Manager of Carolina Longevity Institute, LLC, a biotech and medtech private investment company, from 2017 to 2019; as Chief Executive Officer and Chief Financial Officer of Organ Transport Systems Inc, a privately held medical device company, from 2010 to 2017 and 2005 to 2010, respectively; as Vice President of Sales, Operations and Finance, and Chief Financial Officer for Premier Sourcing Partners Inc., a wholly owned subsidiary of Premier Inc., a privately held medical and information technology product and services company, from 2002 to 2004 and 2000 to 2002, respectively; as Chief Financial Officer of Clarkston-Potomac Group, a privately held ERP implementation and integration services company, from 1998 to 2000; and as Chief Financial Officer of Beacon Eye Institute, a publicly traded provider of Laser Vision Correction equipment and services from 1996 to 1998. Mr. Holder also served as a member of the board of directors of Carolina Longevity Institute, LLC from 2017 to 2019, and as a member of the board of directors of Limitless LLC, a privately held nutraceutical research and development company, from 2018 to 2019. Mr. Holder also served on the board of directors of Organ Transport Systems, Inc. from 2005 to 2017, and Cyphre Inc., a privately held cybersecurity company, from 2016 to 2017.

Mr. Holder holds a B.S. in Business Administration from The Kenan-Flagler Business School at the University of North Carolina at Chapel Hill, and an M.B.A. with a major in Corporate Strategy and Finance from The Wharton School at the University of Pennsylvania. Mr. Holder previously obtained his certified public accountant license (currently inactive).

Vera Imper, Ph.D. has served on our board of directors since December 2021. Dr. Imper served as Vice President and Head, Business Development of Roche Molecular Solutions from January 2018 to November 2021. Dr. Imper previously served as Vice President, Worldwide Business Development of Becton Dickinson Biosciences from May 2009 to October 2017. Dr. Imper currently serves on the advisory board of Barcode Nanotech, a privately funded start-up company. Dr. Imper holds a Ph.D. in Bioinorganic Chemistry, an M.S. in Physical and Organic Chemistry, and a B.S. in Pharmacy and Biochemistry from University of Zagreb.

Deborah Neff has served on our board of directors since 2022 and has served as our lead independent director since 2025. Ms. Neff served as a director on the board of Atomo Diagnostics Limited, an Australian publicly listed rapid diagnostics company, from 2021 to 2025, and on the advisory board of privately funded start-up company Wainamics, Inc. from 2021 to 2025. Since 2020, she has served as the Principal of DJN Consulting, LLC, an executive management, business strategy and operations consulting company. Prior to that, from 2017 to 2020, she served as Chief Executive Officer of Evanostics LLC, an early-stage, private biotechnology company. From 2014 to 2016, she served as the Chief Operating Officer of Complete Genomics Inc., a business unit of BGI-Shenzhen, a publicly traded genomic sequencing and proteomic services company. From 2006 to 2013, she served as the Chief Executive Officer at Pathwork Diagnostics Inc., a privately held molecular diagnostics company, and from 2003 to 2006, she served as the Chief Executive Officer at Predicant Biosciences, formerly a private biotechnology company. Ms. Neff also served as President of BD Biosciences, Inc., a global business segment of Becton Dickinson, from 1995 to 2003. Ms. Neff served on the board of directors of Bio-Rad Laboratories, Inc. from 2011 to 2017, and on the board of directors of Advanced Medical Optics, Inc. from 2003 to 2009. Ms. Neff currently serves as the Executive Trustee and Chair of the University of California, Davis Foundation, as chair of the board of directors of Guide Dogs for the Blind, and on the advisory board of privately funded start-up company Partillion Bioscience Corporation. Ms. Neff holds a B.S. degree in Physiology from the University of California, Davis and completed graduate training and licensure in clinical laboratory science. She has attended executive business programs in finance, marketing, and general management at Wharton, Stanford, and Harvard Business Schools.

Ming Yan, Ph.D. has served as the Chief Technology Officer and a member of our board of directors since 2015. Dr. Yan is also a co-founder of the company. Dr. Yan has over 20 years of experience in research and development. Prior to joining our company, Dr. Yan held research and development positions at AT&T Bell Laboratories, a research and development division of AT&T Communications, a telecommunications company, Lawrence Livermore National Labs, a federal research facility, and BD Biosciences, a biotechnology company. Dr. Yan has published several research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and pending patent applications for his innovations. Dr. Yan holds a B.S. in Physics from Fudan University and a Ph.D. in Electrical Engineering from the City University of New York.